Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • ADVERTISEMENT FEATURE Advertiser retains sole responsibility for the content of this article

Curious2018—Future Insight

Credit: Merck KGaA, Darmstadt, Germany/Eva Speith

“This is the first meeting of its kind,” said Ulrich Betz, vice president of innovation at Merck Biopharma in Darmstadt, Germany, as he opened Curious2018 in July. The conference is one of a number of celebrations of Merck’s 350th birthday, all with the theme “Always curious — imagine the next 350 years” (see ‘350 years young’).

Ulrich Betz, VP of innovation at Merck, opening the conference

Betz was the driving force behind the conference, which welcomed delegates and speakers from around the world and across the scientific disciplines, and was attended by around 1,300 participants. Among the speakers were five Nobel prize-winners, several world renowned scientists including Craig Venter, and representatives of the European Space Agency (ESA) and the US Defense Advanced Research Projects Agency (DARPA) among others.

The conference covered topics including Healthy Lives — new breakthrough therapies and diagnostics; Life Reimagined — synthetic biology and beyond; Materials and Solutions — chemistry and more; Vibrant Digital — the power of in silico; and Bright Future — new ways of working and collaborating. Sessions dealt with humanity’s move from the Stone Age (Society 1.0) to today’s Information Age (Society 4.0), and looked forward to Society 5.0 — a human-centred technological age. And visitors pondered not just how the future might look, but also on the best way to get there.

Sometimes no strategy is the best approach

Scientific research, particularly within companies, is often strategy focused; that means researchers tend to find only the ‘known unknowns’. In contrast, many major discoveries have been ‘unknown unknowns’, found through fundamental research, an open mind and an ability to recognize opportunities, said physicist Daniel Zajfman of the Weizmann Institute of Science in Rehovot, Israel. Examples include liquid crystals that today power smartphone displays, X-rays now routinely used in imaging, and the physics that led to the global positioning system (GPS).

“Strategy should provide direction, not control the process,” said Zajfman. “Beyond strategy, we need knowledgeable, curious, passionate scientists — and we need to give them freedom to think and the ability to take risks and fail.”The work of biotechnologist Craig Venter exemplifies the ethos of curiosity-driven research. His institute, with labs in La Jolla, California, and Rockville, Maryland, has always valued basic research, and as such has been involved in a series of firsts — sequencing the genomes of a free-living organism, a person and a human microbiome, and creating a self-replicating synthetic organism.

Venter described how such exploratory research could still lead to practical applications. “We can now interconvert genetic and digital code, and make phages and vaccines,” he said. “This could mean creating better seasonal flu vaccines with two or three updates in a year, ‘printing’ off vaccines at home, or even DNA ‘transportation’ to Mars within minutes.”

Small questions are good too

People watching Curious2018

Credit: Merck KGaA, Darmstadt, Germany/Eva Speith

Curiosity is driven by questions, and the biggest is how matter became complex, from the elementary particle to the thinking organism. To answer it, humans created science, where “Chemistry bridges physics’ general laws and biology’s rules of life,” said 1987 chemistry Nobel prize-winner Jean-Marie Lehn of the University of Strasbourg in France. “Chemistry is to science what music is to acoustics.”

The development of technologies such as cryo-electron microscopy has given chemists and biologists extraordinary resolution, down to the side chains of amino acids in a protein molecule, to help answer many of life’s difficult questions. “We can now see distinct species of molecules in the same sample,” said 2017 Nobel prize-winner Joachim Frank, a biophysicist at Columbia University in New York. “This is a new era in structural biology.”

Biological chemistry and the manipulation of living cells have been major drivers in healthcare and biotech, which leads Frances Arnold, a chemical engineer at Caltech, o another question: “Evolution wrote DNA, through a process of mutation and natural selection,” she said. “We have altered biology through artificial selection and genetic modification — but what about chemicals not found in biology?”

Arnold has used evolutionary biology techniques to create novel chemicals. Enzymes and whole organisms synthesize non-natural molecules with an efficiency far greater than traditional chemical laboratories.

Angela Belcher, a materials chemist at the Massachusetts Institute of Technology (MIT), has also captured the power of biology. She uses modified bacteriophages to create nanomaterials, such as carbon nanotubes for use in cancer imaging and theranostics, and flexible materials for wearable electronics. Also working in the nanosphere is 2016 Nobel prize-winner Fraser Stoddart, head of the Stoddart Mechanostereochemistry Group in the Department of Chemistry at Northwestern University, who is employing new chemistry to create nanoscale molecular machines including motors, rotors, switches and pumps. Stoddart has advice for the next generation of curious and creative scientists: “Tackle a big problem — and do your own thing.”

Humans, microbes and medicine

Tropical diseases have historically received scant attention from biomedical science, despite the fact that they collectively affect more than a billion people. Parasitic diseases such as Chagas disease, schistosomiasis and leishmaniasis are spreading across Latin America, and many preventable diseases are resurging in developed nations as vaccination rates fall. Antimicrobial resistance is rising, and climate change is driving tropical parasites into temperate zones.

Curiosity can play an important role in what are otherwise strategic and goal-driven projects, such as making affordable versions of vaccines against diseases linked with poverty; developing better formulations of existing disease targets; predicting and preventing the spread of disease; and in considering the interactions of the genome, microbiome, metabolome and environment. What is required is that researchers work together, across disciplines, using international networks to exchange data.

And we should not forget the role of education and communication, said Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine in Houston, Texas. Hotez urged scientists “to engage with the public more, and build scientific literacy into science and medical training”.

350 years young

Starting as a single pharmacy in Darmstadt in 1668, Merck has grown into an international company with a focus on healthcare, life science and performance materials. During this time, it has seen pharmacy shift from an art to a science and been part of the move to industrial production, driven always by curiosity.

Merck will support the development of creative solutions over the next 35 years with a new Future Insight prize. It will bestow its first award of up to €1 million in 2019, with the goal of pandemic preparedness against emerging viral diseases. Future prizes will tackle antibacterial resistance, technology to feed the world’s growing population, and fuel generation by photocatalytic conversion of atmospheric carbon dioxide.

Stefan Oschmann, Merck’s Stefan Oschmann, Chairman of the Executive Board

Stefan Oschmann, Merck’s Chairman of the Executive Board & CEO, announces the Future Insight prize.

Directly after the conference, Merck conducted an anniversary edition of its Innovation Cup, which was contested by around 80 students from all over the world who spent a week to learn from Merck professionals and to develop an idea of their own into a business plan. The €20,000 team prize went to the Life Reimagined team who presented a concept to turn plastics into biologics using engineered E. coli to produce methionine from PET.

Society 5.0

As humans live longer, societies are ageing. And nowhere is this more apparent than in Japan, which has the highest proportion of centenarians on top of a falling birth rate. Shinichi Akaike, senior fellow, National Institute of Science and Technology Policy (NISTEP), and Naohiro Shichijo, director of the Centre for Institutional Research, Tokyo University of Technology, proposed Society 5.0 to meet these challenges. Society 5.0 aims to integrate advances in artificial intelligence (AI), big data processing and the Internet of Things (IoT) to resolve societal challenges such as healthcare and support for older people within a human-centred society.

Yoshiyuki Sankai, of robotics company Cyberdyne, takes a creative approach to realizing Society 5.0: “Imagine yourself standing in the future, looking at the present, then create the technology to make this future.” Sankai’s cyborg-type HAL (hybrid assistive limb) uses the ‘intention signal’ derived from the brain to realize the intended motion of the wearer while inducing functional regeneration; another version of HAL provided is Single Joint Type, which is a compact and easy to use device that could be attached on both upper limb and lower limb. Cyberdyne also develops Lumbar Type which reduces the stress applied on the lumbar region of manual workers during lift and carry to mitigate the risk of back injury.

In Society 5.0, AI will also be an important part of drug discovery and development, said Scott Spangler of IBM Watson Health. In research, AI can provide confidence scoring, validate reasoning and data, and help scientists to interrogate existing knowledge for new connections. This can aid target identification, prediction of gene function, and selection of drug indications.

However, AI’s biggest role isn’t simply to provide answers — it’s going to be to drive curiosity by helping researchers ask better questions. “AI isn’t an oracle,” said Spangler. “It’s an annoying collaborator that constantly says, ‘what about…?’.”

The final frontier

For the really curious scientist there are extra-terrestrial questions, starting with our nearest celestial neighbours. “The Moon is a history book of our own planet,” said ESA astronaut Thomas Reiter. “And we might find proof of past or current life on Mars in the next few years.”

ESA’s planned space missions include the BepiColombo spacecraft, which will head to Mercury in October 2018 to investigate the Sun’s closest planet; and the ExoMars lander, which will land on Mars in November 2018 to study the crust, mantle and core of the planet.

Curious2018 was also the birthplace of the Darmstadt Science Declaration, a global call to action to devote more resources to the advancement of science and technology to enable humanity to solve the challenges of today and to realize the dreams of a better tomorrow. The declaration can be signed online at

The story from Curious2018 — Future Insight is a varied one, picking a route through chemistry, biology, physics and technology. From the hugeness of outer space to the minutiae of molecular machines. From the history of pharmacy to healthcare in Society 5.0. And like the drone-powered balloons, with their curious 3-dimensional flight and ethereal internal light that were present during the official welcome ceremony, ideas from the conference will follow the attendees out of the lecture theatre and into the labs to inspire the next generation of breakthroughs.


Quick links